Literature DB >> 8515425

Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.

R M Keenan1, J Weinstock, J A Finkelstein, R G Franz, D E Gaitanopoulos, G R Girard, D T Hill, T M Morgan, J M Samanen, C E Peishoff.   

Abstract

The further evolution of the imidazole-5-acrylic acid series of nonpeptide angiotensin II receptor antagonists is detailed (for Part 1, see: J. Med. Chem. 1992, 35, 3858). Modifications of the N-benzyl ring substitution were undertaken in an effort to mimic the Tyr4 residue of angiotensin II. Introduction of a p-carboxylic acid on the N-benzyl ring resulted in the discovery of compounds with nanomolar affinity for the receptor and good oral activity. SAR studies of these potent antagonists revealed that the thienyl ring, the (E)-acrylic acid, and the imidazole ring in addition to the two acid groups were important for high potency. Also, overlay comparisons of the parent diacid with both angiotensin II and a representative biphenylyltetrazole nonpeptide angiotensin II receptor antagonist are presented. The parent diacid analog, SK&F 108566 or (E)-3-[2-butyl-1-(4-carboxybenzyl)-1H-imidazole-5-yl]-2-[(2- thienyl)methyl]propenoic acid, is currently in clinical development for the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515425     DOI: 10.1021/jm00065a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Synthesis of imidazol-2-yl amino acids by using cells from alkane-oxidizing bacteria.

Authors:  Annett Mikolasch; Elke Hammer; Frieder Schauer
Journal:  Appl Environ Microbiol       Date:  2003-03       Impact factor: 4.792

2.  Design of CID-cleavable protein cross-linkers: identical mass modifications for simpler sequence analysis.

Authors:  Wynne V Kandur; Athit Kao; Danielle Vellucci; Lan Huang; Scott D Rychnovsky
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

3.  Molecular drug targets and structure based drug design: A holistic approach.

Authors:  Shailza Singh; Balwant Kumar Malik; Durlabh Kumar Sharma
Journal:  Bioinformation       Date:  2006-12-23

Review 4.  Rational Design and Synthesis of AT1R Antagonists.

Authors:  Nikitas Georgiou; Vasileios K Gkalpinos; Spyridon D Katsakos; Stamatia Vassiliou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.